Strategic partnerships Opportunity: Leverage Hesperos Human-on-a-Chip platform to co-develop preclinical safety and efficacy studies for pharma, cosmetics, and food industries, highlighting reduced animal testing and faster pipeline insights. Target partners include large pharma with robust CNS, opioid, or neurodegenerative programs and consumer health brands seeking validated non-animal models.

Collaborations Opportunity: Capitalize on recent collaborations with Bayer Consumer Health and UCF by approaching potential academic-industry joint ventures and contract research opportunities that emphasize human-relevant data, multi-organ modeling, and translational endpoints for complex diseases.

Expansion potential Opportunity: Market the platform to mid to large Biotech firms and CROs needing scalable organ-on-a-chip solutions for multi-organ toxicity and efficacy testing, aligning with Hesperos’ growth in Florida and its international collaboration network.

Technology edge Opportunity: Position as a premium preclinical testing partner offering real-time, non-invasive organ function monitoring and detailed endpoints from gene expression to electrophysiology, appealing to teams seeking more predictive models to de-risk candidates early.

Industry tailwinds Opportunity: Align offerings with sustainability and regulatory trends that favor reduction of animal testing and more human-relevant data, targeting cosmetics and food safety segments alongside traditional pharma to broaden addressable market and pricing leverage.